Omada Health’s (OMDA) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Omada Health (NASDAQ:OMDA) in a report released on Friday,Benzinga reports. They currently have a $28.00 price target on the stock.

OMDA has been the subject of several other reports. BMO Capital Markets restated an “outperform” rating and set a $24.00 target price on shares of Omada Health in a research report on Friday, August 7th. Barclays lifted their price target on Omada Health from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup reissued an “outperform” rating on shares of Omada Health in a report on Friday, August 14th. Wall Street Zen upgraded shares of Omada Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Citizens Jmp raised their target price on shares of Omada Health from $27.00 to $32.00 and gave the company a “market outperform” rating in a research note on Friday, August 14th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Omada Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.67.

Omada Health Price Performance

NASDAQ OMDA opened at $19.66 on Friday. Omada Health has a 1 year low of $10.28 and a 1 year high of $26.92. The stock has a market capitalization of $1.20 billion, a PE ratio of 393.20 and a beta of 1.86. The company’s 50 day simple moving average is $22.63 and its two-hundred day simple moving average is $17.97.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.10. The firm had revenue of $87.83 million during the quarter, compared to the consensus estimate of $80.93 million. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. On average, research analysts anticipate that Omada Health will post 0.09 EPS for the current year.

Insider Buying and Selling at Omada Health

In related news, CEO Sean Duffy sold 25,886 shares of Omada Health stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $22.68, for a total value of $587,094.48. Following the transaction, the chief executive officer owned 411,861 shares in the company, valued at $9,341,007.48. This trade represents a 5.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Steven Cook sold 33,000 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $19.89, for a total transaction of $656,370.00. Following the completion of the sale, the chief financial officer directly owned 133,359 shares of the company’s stock, valued at $2,652,510.51. This represents a 19.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 259,767 shares of company stock worth $5,605,349. 6.38% of the stock is owned by insiders.

Hedge Funds Weigh In On Omada Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in Omada Health during the 2nd quarter valued at $32,000. Quarry LP bought a new position in shares of Omada Health in the 4th quarter worth about $29,000. Integrated Wealth Concepts LLC purchased a new position in Omada Health during the 2nd quarter valued at about $53,000. Versant Capital Management Inc lifted its position in Omada Health by 319.3% during the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after acquiring an additional 2,283 shares during the period. Finally, Legal & General Group Plc bought a new stake in Omada Health during the second quarter worth about $76,000.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Analyst support remains strong: BTIG Research reaffirmed its “buy” rating and set a $35 price target, while Needham & Company also maintained a “buy” rating with a $28 target. These targets imply significant potential upside and reinforce confidence in Omada’s growth outlook.
• Positive Sentiment: Investor Day could provide new growth targets: Omada held its inaugural Investor Day and planned to present updated long-term financial targets. More ambitious revenue, profitability, or membership goals could improve investor confidence if management’s outlook exceeds current expectations. Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day
• Neutral Sentiment: Investor Day transcript available: The transcript may offer additional detail on Omada’s strategy and financial targets, but the supplied report does not identify specific changes that would immediately alter earnings expectations. Omada Health Analyst/Investor Day Transcript
• Negative Sentiment: Chief accounting officer sold shares: CAO Craig Gracey sold 644 shares for approximately $14,000, reducing his direct ownership by 4.28%. The relatively small transaction is not necessarily a sign of deteriorating fundamentals, but insider selling can create short-term negative sentiment. SEC Insider Transaction Filing

About Omada Health

Omada Health, Inc is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines clinical care, health coaching, connected devices, digital tools and personalized support to help members improve health outcomes and manage conditions over time.

The company’s offerings address areas including diabetes, hypertension, weight health and musculoskeletal conditions. Omada’s programs are designed to support prevention and ongoing care through services such as remote monitoring, personalized health guidance, educational content and access to healthcare professionals.

Omada primarily serves members through employers, health plans and healthcare organizations in the United States.